<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04960657</url>
  </required_header>
  <id_info>
    <org_study_id>H19065735</org_study_id>
    <nct_id>NCT04960657</nct_id>
  </id_info>
  <brief_title>The Hemodynamic Effects of PACAP38 After Glibenclamide Administration in Healthy Volunteers</brief_title>
  <official_title>The Hemodynamic Effects of PACAP38 After Glibenclamide Administration in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Danish Headache Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Danish Headache Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the hemodynamic effects of PACAP38 after glibenclamide administration.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      22 healthy participants will randomly be allocated to receive PACAP38 infusion followed by&#xD;
      glibenclamide or placebo on two different days.&#xD;
&#xD;
      The aim of the study is to investigate the vascular effect of PACAP38 after glibenclamide&#xD;
      administration.&#xD;
&#xD;
      Repeated measurements covering the arteria radialis (RA), superficial temporal artery (STA)&#xD;
      and middle cerebral artery (MCA) before and after PACAP38 infusion and glibenclamide/placebo&#xD;
      administration&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 20, 2020</start_date>
  <completion_date type="Actual">March 19, 2021</completion_date>
  <primary_completion_date type="Actual">March 19, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Randomized, double-blind, cross-over, placebo-controlled design in healthy volunteers.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Headache</measure>
    <time_frame>Time of headache measurements is from before (-20 minutes) and up to 12 hours after PACAP38 infusion</time_frame>
    <description>Headache intensity will be recorded by numerical rating scale (NRS) from 0 to 10 (0, no headache; 1, a feeling of pressure; 10, worst imaginable headache).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in the arterial radialis (RA), superficial temporal artery (STA) and middle cerebral artery (MCA).</measure>
    <time_frame>Time of measurements is baseline and repeatedly every 20 minutes for 260 minutes.</time_frame>
    <description>Repeated measurements covering the diameter of RA, STA and MCA before and after PACAP38 infusion and glibenclamide/placebo administration measured by centimeter (cm)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Migraine</condition>
  <condition>Headache</condition>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>PACAP38 and glibenclamide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive glibenclamide after PACAP38 infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PACAP38 and placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive placebo after PACAP38 infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>glibenclamide</intervention_name>
    <description>Oral administration of glibenclamide/placebo. To investigate the role of PACAP38 on cranial arteries in healthy volunteers after glibenclamide/placebo administration .</description>
    <arm_group_label>PACAP38 and glibenclamide</arm_group_label>
    <arm_group_label>PACAP38 and placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PACAP38</intervention_name>
    <description>PACAP38 infusion</description>
    <arm_group_label>PACAP38 and glibenclamide</arm_group_label>
    <arm_group_label>PACAP38 and placebo</arm_group_label>
    <other_name>Pituitary adenylate cyclase activating polypeptide-38</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy volunteers of both sexes.&#xD;
&#xD;
          -  18-60 years.&#xD;
&#xD;
          -  50-100 kg.&#xD;
&#xD;
          -  Women of childbearing age must use adequate contraception&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A history of serious somatic or psychiatric disease&#xD;
&#xD;
          -  Migraine or any other type of headache (except episodic tension-type headache less&#xD;
             than 5 days per month)&#xD;
&#xD;
          -  Daily intake of any medication except contraceptives&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Danish Headache Center</name>
      <address>
        <city>Copenhagen</city>
        <state>Capital Region</state>
        <zip>2600</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>May 24, 2021</study_first_submitted>
  <study_first_submitted_qc>July 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 14, 2021</study_first_posted>
  <last_update_submitted>July 2, 2021</last_update_submitted>
  <last_update_submitted_qc>July 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Danish Headache Center</investigator_affiliation>
    <investigator_full_name>Lili Kokoti</investigator_full_name>
    <investigator_title>MD, PhD student, Principal investigator</investigator_title>
  </responsible_party>
  <keyword>Glyburide</keyword>
  <keyword>Physiological Effects of Drugs</keyword>
  <keyword>Hypoglycemic Agents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Headache</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glyburide</mesh_term>
    <mesh_term>Pituitary Adenylate Cyclase-Activating Polypeptide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

